Cornelis V. T.
- Country
- Germany
- Department
- Päd. Hämatologie und Onkologie
Research Overview
- ONC201 for the Treatment of Newly Diagnosed H3 K27M-mutant Diffuse Glioma Following Completion of Radiotherapy: A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study (The ACTION Study)
- Phase I/II Umbrella Trial of Ulixertinib, Tovorafenib, and Vinblastine Sulfate in Pediatric Patients with Progressive, Relapsed, or Refractory Low-Grade Glioma
- Efficacy and Safety of Tovorafenib in Children and Young Adults with Newly Diagnosed or Recurrent Craniopharyngioma
Data & Insights
Has run more than one trial at 41 of 108 partner sites.
Specializations
Neurological Oncology
This investigator specializes in treating primary CNS tumors and diffuse gliomas, with particular emphasis on molecularly-defined brain cancers including H3 K27M-mutant variants.
- CNS Tumor Management
- Glioma Treatment
- Neuro-oncological Assessment
Their work encompasses both diagnostic and therapeutic approaches for primary and metastatic brain tumors.
Molecular Targeted Therapy
The investigator focuses on precision medicine approaches targeting specific genetic alterations including NTRK fusions, ALK fusion-positive tumors, and KIT/PDGFRA signaling pathways.
- Genetic Biomarker Analysis
- Targeted Drug Development
- Mutation-Specific Treatments
Their expertise extends to implementing novel targeted therapies for rare molecular subtypes of cancer.
Pediatric Oncology
This investigator specializes in treating advanced solid tumors in pediatric patients, with particular focus on tumor-agnostic approaches and precision immuno-oncology.
- Pediatric Clinical Trials
- Advanced Solid Tumors
- Treatment-Resistant Cancers
Their research encompasses innovative therapeutic strategies for children with refractory or relapsed cancers.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.